These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 15573801)
1. Lessons learned after the withdrawal of rofecoxib. Giaquinta D Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801 [No Abstract] [Full Text] [Related]
2. Failing the public health--rofecoxib, Merck, and the FDA. Topol EJ N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193 [No Abstract] [Full Text] [Related]
3. COX-2 inhibitor use after Vioxx: careful balance or end of the rope? Fendrick AM Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263 [No Abstract] [Full Text] [Related]
4. Evaluating drug effects in the post-Vioxx world: there must be a better way. Avorn J Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873 [No Abstract] [Full Text] [Related]
5. Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib). Carné X; Cruz N Eur J Epidemiol; 2005; 20(2):127-9. PubMed ID: 15792277 [No Abstract] [Full Text] [Related]
6. Learning the value of drugs--is rofecoxib a regulatory success story? Eisenberg RS N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222 [No Abstract] [Full Text] [Related]
7. Experts point to lessons learned from controversy over rofecoxib safety. Hampton T JAMA; 2005 Jan; 293(4):413-4. PubMed ID: 15671414 [No Abstract] [Full Text] [Related]
8. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Couzin J Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258 [No Abstract] [Full Text] [Related]